|
 Alessandro Riva will become a Gilead senior vice president and head
of its haematology and oncology therapeutic area, the U.S. company
announced late on Tuesday.
Riva joins from Novartis Oncology, where he was global head of
oncology development. He was responsible for developing more than 20
cancer compounds, including targeted and immune-oncology therapies.
He also oversaw regulatory approvals of new medicines in both solid
and haematological malignancies, Gilead said.
During his 12-year tenure at Novartis Riva was involved in several
worldwide drug approvals, it said.
"I have always admired Gilead for its scientific focus and
data-driven approach to drug development, Riva said in a statement.
[to top of second column] |
Novartis shares were down 1.1 percent by 1055 GMT while the Stoxx
European healthcare sector index was barely changed.
(Reporting by Michael Shields; editing by Jason Neely)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
